ArriVent Says First Patient Dosed in ARR-002 Trial
ArriVent announced that the first patient has been dosed with its MUC16/NAPI2B dual-target ADC, ARR-002.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.